NJ-IEEE
15.9.2021 16:37:03 CEST | Business Wire | Press release
IEEE, the world's largest technical professional organization dedicated to advancing technology for humanity, and the IEEE Standards Association (IEEE SA) today announced the launch of IEEE 7000™-2021 - IEEE Standard Model Process for Addressing Ethical Concerns During System Design that provides a clear methodology to analyze human and social values relevant for an ethical system engineering effort.
IEEE 7000-2021 is recommended for use by organizations that seek to apply broader ethical value criteria and minimize risk, thereby helping to strengthen relationships with their end users and customers. Organizations may apply this first of its kind standard across multiple levels including concept exploration, system requirements definition, or development of new or revised products or services.
“Engineers, their managers, and other stakeholders benefit from well-defined processes for considering ethical issues along with the usual concerns of system performance and functionality early in the system life cycle,” said Konstantinos Karachalios, Managing Director of IEEE SA. “End users can be unaware of the ethical considerations regarding the products and services they use; this is why IEEE supported the launch of the IEEE 7000 series of standards including this standard that also complements our Ethics Certification Program for Autonomous and Intelligent Systems (ECPAIS) certification criteria offering. It is only by rigorously prioritizing ethical concerns at the outset of design that manufacturers, engineers, and technologists can responsibly align products and services with results honoring the contextual values of customers, citizens, and society at large.”
This standard provides:
- a system engineering standard approach integrating human and social values into traditional systems engineering and design.
- processes for engineers to translate stakeholder values and ethical considerations into system requirements and design practices.
- a systematic, transparent, and traceable approach to address ethically-oriented regulatory obligations in the design of autonomous intelligent systems.
“Value-based Engineering (VbE), a methodology providing ways to elicit, conceptualize, prioritize and respect end user values in system design, is at the heart of IEEE 7000-2021 and provides companies with a highly practical approach to master the values based challenges of their digital transformation,” said Dr. Sarah Spiekermann, Chair of The Institute for Information Systems & Society at Vienna University of Economics and Business (WU Vienna) and Vice-Chair of IEEE 7000-2021. "IEEE 7000-2021 test users identified ten issues per person involved in the project, demonstrating that the utilization of value-based Engineering can lead to fewer project risks and exponential innovation. This is a massive improvement relative to current technical roadmap processes."
A key part of digital transformation provided by IEEE 7000-2021 comes in addressing risk. Where traditional evaluations of technological risk may focus largely on areas of physical harm, the VbE methodology provides a broader lens to consider also potential value harms associated with product or systems design. This makes the standard unique and deeply important in terms of ease of adoption of applied ethics methodologies in emerging technologies such as AI.
The use of this standard could help organizations better earn and keep the trust of end-users and stakeholders by directly addressing ethical concerns upfront, leading to greater market acceptance of their products, services, or systems.
For more information, to purchase, or to view a read-only version of the IEEE 7000-2021 Standard, click here .
To learn more about IEEE SA or about any of its many market-driven initiatives, visit us on Facebook , follow us on Twitter , connect with us on LinkedIn , or on the Beyond Standards Blog .
About the IEEE Standards Association
IEEE Standards Association (IEEE SA) is a collaborative organization where innovators raise the world's standards for technology. IEEE SA provides a globally open, consensus-building environment and platform that empowers people to work together in the development of leading-edge, market-relevant technology standards, and industry solutions shaping a better, safer, and sustainable world. For more information, visit https://standards.ieee.org .
About IEEE
IEEE is the world’s largest technical professional organization dedicated to advancing technology for the benefit of humanity. Through its highly cited publications, conferences, technology standards, and professional and educational activities, IEEE is the trusted voice in a wide variety of areas ranging from aerospace systems, computers, and telecommunications to biomedical engineering, electric power, and consumer electronics. Learn more at https://www.ieee.org .
View source version on businesswire.com: https://www.businesswire.com/news/home/20210915005012/en/
Link:
Social Media:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
2PointZero Group Signals Global Scale With Revenue Surge to AED 21.9 Billion and Net Profit of AED 7.7 Billion in H1 202631.7.2026 13:42:00 CEST | Press release
Group revenue growth supported by stable gross profit margin of 29%, and adjusted EBITDA of AED 5.0 billionGlobal expansion milestones include the completed sale of TAQA stake, and the acquisition of Traverse Midstream Partners in North America, Baobab Group in Africa, and 60.8% of ISEM in ItalyTIME ranks the Group 36th on the World’s Growth Leaders list for 2026, highlighting market stability, operational scale and disciplined approach to capital 2PointZero Group (ADX: 2POINTZERO), a leading Abu Dhabi-based investment holding firm, announced its financial results for the first half of 2026, reporting revenue of AED 21.9 billion and delivering a Group Net Profit of AED 7.7 billion. This robust performance is reflected in the Group’s adjusted EBITDA, which reached AED 5.0 billion after excluding fair value changes and one-offs. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260731538982/en/ Samia Bouazza, CEO of 2PointZero (P
Datroway® Approved in the EU as Only TROP2 Directed Medicine with Overall Survival Benefit for the First-Line Treatment of Patients with Metastatic TNBC Who Are Not Candidates for Immunotherapy31.7.2026 08:30:00 CEST | Press release
Approval based on TROPION-Breast02 phase 3 trial results where Daiichi Sankyo and AstraZeneca’s Datroway showed a statistically significant and clinically meaningful improvement for the dual primary endpoints of overall survival and progression-free survival Datroway now approved for two breast cancer indications in the EU Datroway® (datopotamab deruxtecan) has been approved in the European Union (EU) as monotherapy for the first-line treatment of adult patients with unresectable or metastatic triple negative breast cancer (TNBC) who are not candidates for PD-1/PD-L1 inhibitor therapy. Datroway is a specifically engineered TROP2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The approval by the European Commission follows the positive opinionof the Committee for Medicinal Products for Human Use of the European Medicines Agency and is based on result
Polpharma Biologics Announces FDA and EMA Acceptance for Review of PB016 Vedolizumab Biosimilar Candidate31.7.2026 08:30:00 CEST | Press release
Polpharma Biologics International AG today announces that the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA) have accepted for review the Biologics License Application (BLA) and Marketing Authorisation Application (MAA), respectively, for PB016, a proposed vedolizumab biosimilar candidate to Takeda’s reference product Entyvio®* (vedolizumab) lyophilized vial for intravenous (IV) administration for the treatment of adults with moderately to severely active ulcerative colitis and Crohn's disease. The BLA and MAA acceptances represent significant milestones in Polpharma Biologics' development program and underscore the company's commitment to advancing high-quality biosimilars and expanding global access to affordable biologic medicines. "FDA and EMA acceptances for review of our IV vedolizumab biosimilar candidate mark a major achievement for Polpharma Biologics and validate our deep scientific expertise in biosimilar development and manufacturing," said
SES: Disclosure of Share Buyback Transactions31.7.2026 07:30:00 CEST | Press release
In the time period from June 2, 2026 until and including June 23, 2026, a number of 213,167 shares were bought back within the framework of the share buyback of SES to meet obligations under SES’s Equity Based Compensation Plan (EBCP). Shares were bought back as follows: Day of purchase Aggregated volume in shares Daily weighted average acquisition price of shares (EUR) Market June 2, 2026 27,097 8.8727 DXE June 2, 2026 72,903 8.8556 ENX June 5, 2026 16,624 8.3723 DXE June 5, 2026 31,510 8.4266 ENX June 15, 2026 26,451 7.8423 XPAR June 17, 2026 26,812 7.3910 XPAR June 23, 2026 11,770 7.2200 XPAR The transactions in a detailed form are published on SES’s website: https://www.ses.com/investors/shareholder-information/share-buy-backs. Follow us on: Twitter | Facebook | YouTube | LinkedIn | Instagram Read our Blogs > Visit the Media Gallery > About SES At SES, we believe that space has the power to make a difference. That’s why we design space solutions that help governments protect, busin
Half-Year Report on SES’s Liquidity Contract31.7.2026 07:30:00 CEST | Press release
Pursuant to the liquidity contract entered into by SES with BNP Paribas as of 7 April 2026, please see the below update on the progress of the liquidity services. When the liquidity services were implemented as of 7 April 2026, the following assets were in the liquidity account: € 2,500,000 As of 30 June 2026, the following assets appeared on the liquidity account: 228,186 shares; € 816,880. Over the period from 7 April 2026 to 30 June 2026, the following transactions were executed: 1,082 buy transactions; 1,308 sales transactions. Over this same period, the volumes traded represented: 1,093,335 shares and € 8,485,986 on the buy side; 873,399 shares and € 6,860,843 on the sell side. Follow us on: LinkedIn | Facebook | YouTube | X | Instagram Read our Blogs > Visit the Media Gallery > About SES At SES, we believe that space has the power to make a difference. That’s why we design space solutions that help governments protect, businesses grow, and people stay connected—no matter where th
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
